{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=64",
    "query": {
      "intervention": "Placebo Intravenous",
      "page": 64
    },
    "page_size": 10
  },
  "pagination": {
    "page": 64,
    "page_size": 10,
    "total_count": 2347,
    "total_pages": 235,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=65&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+Intravenous&page=63&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-17T11:59:15.252Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02127970",
      "title": "Single Dose vs. Two Dose Regimen of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Abscess",
        "Wound Infection",
        "Surgical Site Infection",
        "Cellulitis"
      ],
      "interventions": [
        {
          "name": "Dalbavancin",
          "type": "DRUG"
        },
        {
          "name": "Dalbavancin-matching Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Durata Therapeutics Inc., an affiliate of Allergan plc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 698,
      "start_date": "2014-04-18",
      "completion_date": "2015-03-11",
      "has_results": true,
      "last_update_posted_date": "2018-09-28",
      "last_synced_at": "2026-10-17T11:59:15.252Z",
      "location_count": 25,
      "location_summary": "Montgomery, Alabama • Anaheim, California • Long Beach, California + 18 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Modesto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02127970"
    },
    {
      "nct_id": "NCT03985410",
      "title": "Study Evaluating the Effect of ETX2514 on Cardiac Repolarization in Healthy Male or Female Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acinetobacter Baumannii-calcoaceticus Complex Infections"
      ],
      "interventions": [
        {
          "name": "ETX2514",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "moxifloxacin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Entasis Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 32,
      "start_date": "2019-05-23",
      "completion_date": "2019-07-24",
      "has_results": false,
      "last_update_posted_date": "2019-08-30",
      "last_synced_at": "2026-10-17T11:59:15.252Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03985410"
    },
    {
      "nct_id": "NCT00862641",
      "title": "A Study of the Safety and Tolerance of Regadenoson in Subjects With Asthma or Chronic Obstructive Pulmonary Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma",
        "Coronary Artery Disease",
        "Pulmonary Disease, Chronic Obstructive"
      ],
      "interventions": [
        {
          "name": "Regadenoson",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1009,
      "start_date": "2009-04",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2012-09-18",
      "last_synced_at": "2026-10-17T11:59:15.252Z",
      "location_count": 48,
      "location_summary": "Montgomery, Alabama • Anaheim, California • Encinitas, California + 43 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Huntington Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00862641"
    },
    {
      "nct_id": "NCT01492374",
      "title": "Study to Evaluate the Safety, Tolerability and the Effect of BMS-241027 on Cerebrospinal Fluid Biomarkers in Subjects With Mild Alzheimer's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "BMS-241027",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching BMS-241027",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "50 Years to 90 Years"
      },
      "enrollment_count": 40,
      "start_date": "2012-02",
      "completion_date": "2013-10",
      "has_results": false,
      "last_update_posted_date": "2014-07-24",
      "last_synced_at": "2026-10-17T11:59:15.252Z",
      "location_count": 15,
      "location_summary": "Anaheim, California • Long Beach, California • San Francisco, California + 11 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Boulder",
          "state": "Colorado"
        },
        {
          "city": "Fairfield",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01492374"
    },
    {
      "nct_id": "NCT02257580",
      "title": "The Effect of Intravenous EACA on Blood Loss and Transfusion Requirements After Bilateral VRO",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "E-Aminocaproic Acid",
        "Bilateral Varus Rotational Osteotomy"
      ],
      "interventions": [
        {
          "name": "E-Aminocaproic acid",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hospital for Special Surgery, New York",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "1 Year to 18 Years"
      },
      "enrollment_count": 28,
      "start_date": "2015-04-01",
      "completion_date": "2020-10-26",
      "has_results": true,
      "last_update_posted_date": "2022-11-23",
      "last_synced_at": "2026-10-17T11:59:15.252Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02257580"
    },
    {
      "nct_id": "NCT07639359",
      "title": "Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Critical Illness",
        "Depressive Symptoms"
      ],
      "interventions": [
        {
          "name": "Ketamine (0.5 mg/kg)",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline (0.9% NaCl)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Hospital Italiano de Buenos Aires",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 50,
      "start_date": "2026-05-14",
      "completion_date": "2028-06-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-17T11:59:15.252Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07639359"
    },
    {
      "nct_id": "NCT05065970",
      "title": "Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Immunoglobulin A (IgA) Nephropathy"
      ],
      "interventions": [
        {
          "name": "Felzartamab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "HI-Bio, A Biogen Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 54,
      "start_date": "2021-08-31",
      "completion_date": "2024-05-06",
      "has_results": true,
      "last_update_posted_date": "2026-04-28",
      "last_synced_at": "2026-10-17T11:59:15.252Z",
      "location_count": 4,
      "location_summary": "Oxnard, California • Vacaville, California • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Oxnard",
          "state": "California"
        },
        {
          "city": "Vacaville",
          "state": "California"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "El Paso",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05065970"
    },
    {
      "nct_id": "NCT03420768",
      "title": "A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatic Cirrhosis",
        "Liver Fibrosis"
      ],
      "interventions": [
        {
          "name": "BMS-986263",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 61,
      "start_date": "2018-02-14",
      "completion_date": "2019-05-28",
      "has_results": true,
      "last_update_posted_date": "2022-02-04",
      "last_synced_at": "2026-10-17T11:59:15.252Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03420768"
    },
    {
      "nct_id": "NCT04545060",
      "title": "VIR-7831 for the Early Treatment of COVID-19 in Outpatients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Covid19"
      ],
      "interventions": [
        {
          "name": "VIR-7831 (sotrovimab)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Vir Biotechnology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1057,
      "start_date": "2020-08-27",
      "completion_date": "2021-09-02",
      "has_results": true,
      "last_update_posted_date": "2022-11-07",
      "last_synced_at": "2026-10-17T11:59:15.252Z",
      "location_count": 63,
      "location_summary": "Anniston, Alabama • Cullman, Alabama • Mesa, Arizona + 49 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04545060"
    },
    {
      "nct_id": "NCT03251482",
      "title": "A Study to Evaluate the Safety and Efficacy of Intravenous JNJ-64179375 Versus Oral Apixaban in Participants Undergoing Elective Total Knee Replacement Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "VTE Prophylaxis With Anticoagulation After Total Knee Replacement Surgery"
      ],
      "interventions": [
        {
          "name": "JNJ-64179375 0.3 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 0.6 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 1.2 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 (Dose to be Determined)",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 A mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 B mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 C mg/kg",
          "type": "DRUG"
        },
        {
          "name": "JNJ-64179375 D mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Placebo JNJ-64179375",
          "type": "DRUG"
        },
        {
          "name": "Apixaban placebo",
          "type": "DRUG"
        },
        {
          "name": "Apixaban 2.5 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Research & Development, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 308,
      "start_date": "2017-11-13",
      "completion_date": "2018-11-05",
      "has_results": true,
      "last_update_posted_date": "2019-11-25",
      "last_synced_at": "2026-10-17T11:59:15.252Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • Torrance, California • Englewood, Colorado + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Torrance",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "DeLand",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03251482"
    }
  ]
}